产品
编 号：F458537
分子式：C27H32O16
分子量：612.53
分子式：C27H32O16
分子量：612.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
350
询价
5mg
230
询价
10mg
320
询价
25mg
580
询价
50mg
820
询价
100mg
1060
询价
结构图
CAS No: 78281-02-4
产品详情
生物活性：
Hydroxysafflor yellow A (Safflomin A) is a natural product of flavonoids isolated from safflower. Hydroxysafflor yellow A can inhibit cell proliferation and promote apoptosis through the autophagy pathway. Hydroxysafflor yellow A has anti-inflammatory, antioxidant and antitumor effects. Hydroxysafflor yellow A can be used in the study of cardiovascular disease.
体内研究：
Hydroxysafflor yellow A (2.5 或 10 mg/kg/day, 腹腔注射, 连续 6 周) 通过增强肝组织抗氧化能力、抑制 TGF-β1 表达保护大鼠肝脏免受长期酒精损伤。Hydroxysafflor yellow A (30, 48, 76.8 mg/kg, 腹腔注射) 通过减弱 NF-κB 和 p38MAPK 信号转导对慢性阻塞性肺疾病大鼠炎性损伤具有保护作用。Hydroxysafflor yellow A (1.135, 2.25 mg/kg 腹腔注射) 在裸鼠肿瘤模型中可抑制肿瘤生长，阻断肝癌细胞自噬。Animal Model:Liver injury model induced by alcohol
Dosage:2.5 or 10 mg/kg
Administration: i.p. daily for 6 weeks
Result:Decreased the level of ALT and AST. Decreased the levels of HA, LN, and III-C.Increased the activities of SOD and GPx and decreased the level of TGF-β1 expression.
Animal Model:Chronic obstructive pulmonary disease (COPD)
Dosage:30, 48, 76.8 mg/kg
Administration:i.p.
Result:Inhibited the elevated IL-6, IL-1β, TNF-α, ICAM-1 and VCAM-1 mRNA Levels.Inhibited the increased phosphorylation and NF-κB p65 levels.
体外研究：
Hydroxysafflor yellow A (10 μM, 24 h) 通过 toll 样受体 -4 途径抑制脂多糖诱导的血管平滑肌细胞的增殖和迁移。Hydroxysafflor yellow A (0.01-10 mg/L, 4-96 h) 通过提高 HSL 启动子活性来促进脂溶特异性酶 HSL 的表达来抑制 3T3-L1 前脂肪细胞的增殖和脂肪形成。Hydroxysafflor yellow A (1-100 μM, 12-24 h) 通过抑制 p38 MAPK 磷酸化、 NF-κB活化、炎症因子高表达和白细胞对 EC 的粘附降低 LPS 诱导的 EC 炎症损伤。Hydroxysafflor yellow A (20-160 μM, 24-48 h) 通过阻断肝癌细胞自噬通量抑制细胞增殖和促进细胞凋亡。
Hydroxysafflor yellow A (Safflomin A) is a natural product of flavonoids isolated from safflower. Hydroxysafflor yellow A can inhibit cell proliferation and promote apoptosis through the autophagy pathway. Hydroxysafflor yellow A has anti-inflammatory, antioxidant and antitumor effects. Hydroxysafflor yellow A can be used in the study of cardiovascular disease.
体内研究：
Hydroxysafflor yellow A (2.5 或 10 mg/kg/day, 腹腔注射, 连续 6 周) 通过增强肝组织抗氧化能力、抑制 TGF-β1 表达保护大鼠肝脏免受长期酒精损伤。Hydroxysafflor yellow A (30, 48, 76.8 mg/kg, 腹腔注射) 通过减弱 NF-κB 和 p38MAPK 信号转导对慢性阻塞性肺疾病大鼠炎性损伤具有保护作用。Hydroxysafflor yellow A (1.135, 2.25 mg/kg 腹腔注射) 在裸鼠肿瘤模型中可抑制肿瘤生长，阻断肝癌细胞自噬。Animal Model:Liver injury model induced by alcohol
Dosage:2.5 or 10 mg/kg
Administration: i.p. daily for 6 weeks
Result:Decreased the level of ALT and AST. Decreased the levels of HA, LN, and III-C.Increased the activities of SOD and GPx and decreased the level of TGF-β1 expression.
Animal Model:Chronic obstructive pulmonary disease (COPD)
Dosage:30, 48, 76.8 mg/kg
Administration:i.p.
Result:Inhibited the elevated IL-6, IL-1β, TNF-α, ICAM-1 and VCAM-1 mRNA Levels.Inhibited the increased phosphorylation and NF-κB p65 levels.
体外研究：
Hydroxysafflor yellow A (10 μM, 24 h) 通过 toll 样受体 -4 途径抑制脂多糖诱导的血管平滑肌细胞的增殖和迁移。Hydroxysafflor yellow A (0.01-10 mg/L, 4-96 h) 通过提高 HSL 启动子活性来促进脂溶特异性酶 HSL 的表达来抑制 3T3-L1 前脂肪细胞的增殖和脂肪形成。Hydroxysafflor yellow A (1-100 μM, 12-24 h) 通过抑制 p38 MAPK 磷酸化、 NF-κB活化、炎症因子高表达和白细胞对 EC 的粘附降低 LPS 诱导的 EC 炎症损伤。Hydroxysafflor yellow A (20-160 μM, 24-48 h) 通过阻断肝癌细胞自噬通量抑制细胞增殖和促进细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备